Sarah Sammons, Co-Leader of Breast Oncology at UMGCCC and former Senior Physician at Dana-Farber, shared a post by Annals of Oncology on LinkedIn, adding:
“More evidence that the benefits of chemo in premenopausal genetically low risk ER+ breast cancer are due to ovarian suppression and not cytotoxicity.
We need more research in optimal Ovarian Suppression techniques, length and most importantly side effect support!”
Quoting Annals of Oncology:
“New data from the phase III RxPONDER trial. Measures of ovarian reserve could help refine selection to chemotherapy for patients with HR-positive, HER2-negative, node-positive breast cancer.
In RxPONDER, among premenopausal patients aged<55, those with low AMH levels did not benefit from chemotherapy.”
Title: Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)
Authors: K. Kalinsky, W. E. Barlow, H. B. Pathak, R. V. Puri, A. Mitra, T. Home, J. Gralow, K. S. Albain, D. F. Hayes, S. Delaloge, N. U. Lin, E. A. Perez, L. J. Goldstein, S. K. L. Chia, P. Rastogi, A. F. Schott, E. Brain, J.-Y. Pierga, J.-M. Ferrero, S. Shak, D. Tripathy, G. N. Hortobagyi, F. Meric-Bernstam, P. Sharma, L. Pusztai, A. Thompson, A. K. Godwin
Read the full article.
You may also find this interesting:
HER2-Low and HER2-Ultralow: What the Categories Change in Practice